## 3 Results
### Clinical and Functional Results  
Between the pre-pandemic and the pandemic period, the mean ACT score insignificantly increased from 21.5 \(\pm\) 2.8 to 23.0 \(\pm\) 3.9 (\(p\) = 0.1) (Table 2). Due to lockdown limitations, FEV\({}_{1}\) was recorded before and during the pandemic only in seven patients, resulting in mean values of 1.9 \(\pm\) 0.6 L and 1.9 \(\pm\) 0.5 L detected before and during the pandemic, respectively (\(p\) = 0.9). The exacerbation rate was very low, with mean values of 0.3 \(\pm\) 0.6 and 0.5 \(\pm\) 1.5 recorded before and during the pandemic, respectively (\(p\) = 0.3) (Table 2). Therefore, enrolled patients did not require therapeutic changes. When considering some variables related to disease management during pre-pandemic and pandemic periods, statistically significant differences were found in the median number of lung function tests, 1.0 (0.0-1.0) vs. 0.0 (0.0-0.75), respectively (\(p\) < 0.01). A significant difference was also detected with regard to the mean number of outpatient visits (5.2 \(\pm\) 3.8 vs. 0.9 \(\pm\) 2.5, respectively) (\(p\) < 0.0001). On the contrary, the median number of routine blood tests did not show any significant variation between the two periods, 0.0 (0.0-1.0) vs. 0.0 (0.0-1.0), respectively (\(p\) = 0.8).  
\begin{table}
\begin{tabular}{l l l l l} \hline \hline  & \multicolumn{2}{c}{**Pre-Pandemic**} & \multicolumn{2}{c}{**Pandemic**} \\  & **(Median \(\pm\) SD)** & **(Median \(\pm\) SD)** & **(Median \(\pm\) SD)** & **\(p\)-Value** \\ \hline Biologic administration & & & & \\ At hospital & 9 \(\pm\) 2.9 & 1 \(\pm\) 4.5 & \(<\)0.0001 \\ At medical office & 0 \(\pm\) 0.8 & 1 \(\pm\) 4 & 0.007 \\ At home & 0 \(\pm\) 0.2 & 0 \(\pm\) 4.1 & 0.04 \\ _Meplizumab_ & & & \\ Spirometry & 1 \(\pm\) 0 & 0 \(\pm\) 0.5 & 0.25 \\ FEV\({}_{1}\) & 1.5 \(\pm\) 0 & 1.5 \(\pm\) 0 & not available \\ ACT & 20 \(\pm\) 0.5 & 24 \(\pm\) 0.5 & 0.006 \\ Blood tests & 0 \(\pm\) 0.5 & 0.5 \(\pm\) 1 & 0.5 \\ Clinical examination & 6 \(\pm\) 2.2 & 0 \(\pm\) 0.5 & 0.02 \\ Exacerbations & 0.5 \(\pm\) 0.6 & 0 \(\pm\) 0 & 0.18 \\ Biologic administration & & & \\ At hospital & 6 \(\pm\) 0 & 2 \(\pm\) 2.6 & 0.08 \\ At medical office & 0 \(\pm\) 0 & 4 \(\pm\) 2.6 & 0.08 \\ At home & 0 \(\pm\) 0 & 0 \(\pm\) 0 & not available \\ _Benallizumab_ & & & \\ Spirometry & 3 \(\pm\) 1.1 & 0 \(\pm\) 0 & 0.02 \\ FEV\({}_{1}\) & not available & not available & not available \\ ACT & 24 \(\pm\) 0.5 & 24 \(\pm\) 2.2 & 0.7 \\ Blood tests & 1 \(\pm\) 1.4 & 1 \(\pm\) 0.5 & 0.2 \\ Clinical examination & 3 \(\pm\) 0.6 & 0 \(\pm\) 0 & \(<\)0.0001 \\ Exacerbations & 0 \(\pm\) 0 & 0 \(\pm\) 0 & not available \\ Biologic administration & & & \\ At hospital & 3 \(\pm\) 0 & 0 \(\pm\) 0.4 & \(<\)0.0001 \\ At medical office & 0 \(\pm\) 0 & 0 \(\pm\) 1.3 & 0.18 \\ At home & 0 \(\pm\) 0 & 3 \(\pm\) 1.5 & 0.008 \\ \hline \hline \end{tabular}
\end{table}
Table 1: \(Cont.\)  
\begin{table}
\begin{tabular}{l l l l l l} \hline \hline  & \multicolumn{2}{c}{**Males**} & \multicolumn{2}{c}{**Females**} \\  & Pre-Pandemic & Pandemic & & \\  & (Median \(\pm\) SD) & (Median \(\pm\) SD) & \(p\)-Value & Pre-Pandemic & Pandemic \\  & (Median \(\pm\) SD) & (Median \(\pm\) SD) & (Median \(\pm\) SD) & \(p\)-Value \\ \hline _Omalizumab_ & & & & \\ Spirometry & 0 \(\pm\) 0.5 & 0 \(\pm\) 0.7 & 0.4 & 0 \(\pm\) 0.5 & 0 \(\pm\) 0.6 & 0.6 \\ FEV\({}_{1}\) & 2.1 \(\pm\) 0.7 & 1.8 \(\pm\) 0.7 & not available & 2.1 \(\pm\) 0.6 & 2 \(\pm\) 0.6 & not available \\ ACT & 21 \(\pm\) 2.9 & 25 \(\pm\) 4.9 & 0.22 & 21 \(\pm\) 2.8 & 25 \(\pm\) 4.7 & 0.7 \\ Blood tests & 0 \(\pm\) 0.3 & 0 \(\pm\) 2.8 & 0.3 & 0 \(\pm\) 0.3 & 0 \(\pm\) 2.4 & 0.3 \\ \hline \hline \end{tabular}
\end{table}
Table 2: Clinical data related to omalizumab, benalizumab, and mepolizumab administration, sorted for gender.